Abstract Number: Esoc2026a2064 Enhancing LDL-C Management - Patient-Reported Experience of Inclisiran for Secondary Prevention: Real-World Evidence From Rural Primary Care Patients in England

Abstract Background and aims Patients with prior cerebrovascular accident (CVA) remain at high risk of recurrent vascular events. Sustained low-density lipoprotein cholesterol (LDL-C) reduction is a cornerstone of secondary stroke prevention, yet long-term adherence to oral lipid-lowering therapy is often limited by polypharmacy and treatment burden. Inclisiran, a small-interfering RNA therapy with a twice-yearly administration schedule, may address these challenges. Methods An anonymised patient survey was conducted in primary care among adults with established ASCVD, including those with CVA, who received Inclisiran between 2022 and 2024. A 16-item questionnaire assessed demographics, perceived treatment indication, administration experience, side effects, satisfaction, adherence, shared decision-making, understanding of therapy, and perceived impact on medication burden. Quantitative data were analysed descriptively, and free-text responses underwent thematic analysis. Ethics approval was granted. Results 105 patients responded. Inclisiran was reported as easy to receive by 86.0% , with 86.9% describing themselves as “very satisfied” or “satisfied.” Preference for twice-yearly injection over daily oral lipid-lowering therapy was expressed by 79.8%, reflecting a perceived reduction in pill burden. Self-reported adherence was 100%. Side effects were infrequent; 13.0% reported mild local injection-site reactions. Despite high acceptability, only 10.1% reported a good understanding of Inclisiran’s mechanism of action, and 58.6% requested additional information. While 50.5% felt involved in treatment decisions, 21.6% reported limited involvement. Conclusions Inclisiran is highly acceptable and well-tolerated for secondary prevention in real-world primary care, with patient preference driven by reduced pill burden and good adherence. Enhancing patient education and shared decision-making may further optimise LDL-C control and long-term risk reduction after CVA. Conflict of interest Dr C Deaney has received honoraria/grants from Amarin, Amenarini, AZ, Chiesi, Daiichi Sankyo, Ferring, GSK, Idorsia, Novartis, and Novo Nordisk.